363 related articles for article (PubMed ID: 23915644)
1. Fibrosis: a key feature of Fabry disease with potential therapeutic implications.
Weidemann F; Sanchez-Niño MD; Politei J; Oliveira JP; Wanner C; Warnock DG; Ortiz A
Orphanet J Rare Dis; 2013 Aug; 8():116. PubMed ID: 23915644
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
Lenders M; Brand E
Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
[TBL] [Abstract][Full Text] [Related]
3. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
Schaefer RM; Tylki-Szymańska A; Hilz MJ
Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
[TBL] [Abstract][Full Text] [Related]
5. Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease.
Nowak A; Koch G; Huynh-Do U; Siegenthaler M; Marti HP; Pfister M
Kidney Blood Press Res; 2017; 42(1):1-15. PubMed ID: 28253518
[TBL] [Abstract][Full Text] [Related]
6. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
7. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
Waldek S; Feriozzi S
BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
[TBL] [Abstract][Full Text] [Related]
9. Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.
Shimohata H; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
CEN Case Rep; 2020 Aug; 9(3):237-242. PubMed ID: 32189245
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease: a review of current management strategies.
Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
[TBL] [Abstract][Full Text] [Related]
11. Treatment of fabry disease: current and emerging strategies.
Rozenfeld P; Neumann PM
Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
[TBL] [Abstract][Full Text] [Related]
12. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.
Caballero L; Climent V; Hernández-Romero D; Quintanilla MA; de la Morena G; Marín F
Curr Med Chem; 2010; 17(16):1679-89. PubMed ID: 20345350
[TBL] [Abstract][Full Text] [Related]
14. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
15. Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta.
Ito S; Ogura M; Kamei K; Matsuoka K; Warnock DG
Pediatr Nephrol; 2016 Aug; 31(8):1369-73. PubMed ID: 27129690
[TBL] [Abstract][Full Text] [Related]
16. Antibody Epitope of Human α-Galactosidase A Revealed by Affinity Mass Spectrometry: A Basis for Reversing Immunoreactivity in Enzyme Replacement Therapy of Fabry Disease.
Kukacka Z; Iurascu M; Lupu L; Rusche H; Murphy M; Altamore L; Borri F; Maeser S; Papini AM; Hennermann J; Przybylski M
ChemMedChem; 2018 May; 13(9):909-915. PubMed ID: 29473701
[TBL] [Abstract][Full Text] [Related]
17. Anderson-Fabry disease: developments in diagnosis and treatment.
Mehta AB
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S66-74. PubMed ID: 20040315
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
[TBL] [Abstract][Full Text] [Related]
19. The kidney in Fabry's disease.
Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
[TBL] [Abstract][Full Text] [Related]
20. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
